Delivery Order SPE2DB22D2211-SPE2DB25FSCAY
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a $1,694.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens on July 31, 2025, with an ultimate completion date of August 1, 2025. The contract was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,227.36 to supply Lantus SoloStar 100 Unit/ML 3ML insulin pens. This non-competitive, firm fixed price delivery order was issued on July 30, 2025, with an ultimate completion date of July 31, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $3,049.07 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed price contract, with an ultimate completion date of July 24, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was competitively awarded with no set-aside designation, with performance to be executed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $1,534.20 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value pharmaceutical procurement supporting military and federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, valued at $1,022.80 with firm fixed pricing. This non-set-aside delivery order was awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The product is a prescription insulin delivery system used for diabetes management within the...
- The Defense Logistics Agency awarded a $1,317.48 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Lantus SoloStar insulin 100 unit/mL in 3 mL pens. This non-set-aside, competitively awarded contract carries a ceiling value of $2,171.76 with firm fixed pricing and an ultimate completion date of August 4, 2025. The pharmaceutical distributor will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $6,703.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a single delivery order for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin in 3ml quantities. This firm fixed price, competitively awarded contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction executed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order with no set-aside designation, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing indefinite...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCAYDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,461.26 for Lantus SoloStar 100 Unit/ML insulin pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement to support federal medical supply needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The issuance of this diabetes medication delivery order reflects the company's critical role in supplying specialty pharmaceuticals through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/1/25 |